A Chinese Cohort of Cervical Large Cell Neuroendocrine Carcinoma

NCT07240753 | Not Yet Recruiting DMC

• 1 other identifier: TJ-IRB202506084
• Study Type: observational
• Target: 200
• Locations: 0 countries
• Sites: N/A

Brief Summary

Cervical large cell neuroendocrine carcinoma (LCNEC) exhibits highly aggressive biological behavior, including strong invasiveness, a high propensity for metastasis, drug resistance, and poor prognosis, necessitating heightened clinical and pathological awareness. This study aims to summarize the clinical characteristics of LCNEC and analyze various prognostic factors to enhance understanding and vigilance toward this disease. Combined with precise pathological diagnosis, improving diagnostic accuracy is crucial for formulating treatment strategies and assessing patient prognosis.

Conditions

Uterine Cervical Neoplasms

Keywords

Cervical Large Cell Neuroendocrine Carcinoma; Prognosis; High-Risk Factors; Treatment Options

Outcome Measures

Primary Outcomes (2)

• Overall Survival

  One month post-enrollment completion and then annual follow-up

• Disease Recurrence

  One month post-enrollment completion and then annual follow-up

Study Arms (1)

Cervical Large Cell Neuroendocrine Carcinoma Cohort

Other: Postoperative pathological examination confirmed cervical large cell neuroendocrine carcinoma.

Interventions

Postoperative pathological examination confirmed cervical large cell neuroendocrine carcinoma. OTHER

Postoperative pathological examination confirmed cervical large cell neuroendocrine carcinoma.

Cervical Large Cell Neuroendocrine Carcinoma Cohort

Eligibility Criteria

• Sex: female
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Female patients diagnosed with cervical large cell neuroendocrine carcinoma by postoperative histopathological examination.

Sponsors & Collaborators

• Lili: lead
• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology: collaborator
• Cancer Research Institute of Zhongshan City: collaborator
• The First Affiliated Hospital of Zhengzhou University: collaborator
• Qilu Hospital of Shandong University: collaborator
• Fujian Province Tumor Hospital: collaborator
• Fujian Maternity and Child Health Hospital: collaborator
• Zhejiang Cancer Hospital: collaborator
• The Third Affiliated Hospital of Kunming Medical College.: collaborator
• Obstetrics & Gynecology Hospital of Fudan University: collaborator
• Women's Hospital School Of Medicine Zhejiang University: collaborator
• National Cancer Center/National Cancer Clinical Medical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College: collaborator
• Peking Union Medical College Hospital: collaborator
• The Affiliated Tumor Hospital of Xinjiang Medical University: collaborator
• The First Affiliated Hospital of Anhui Medical University: collaborator
• Tianjin Medical University Cancer Institute and Hospital: collaborator
• Renmin Hospital of Wuhan University: collaborator

Related Publications (6)

• Takayanagi D, Hirose S, Kuno I, Asami Y, Murakami N, Matsuda M, Shimada Y, Sunami K, Komatsu M, Hamamoto R, Kato MK, Matsumoto K, Kohno T, Kato T, Shiraishi K, Yoshida H. Comparative Analysis of Genetic Alterations, HPV-Status, and PD-L1 Expression in Neuroendocrine Carcinomas of the Cervix. Cancers (Basel). 2021 Mar 10;13(6):1215. doi: 10.3390/cancers13061215.

  PMID: 33802174 BACKGROUND

• Georgescu TA, Bohiltea RE, Munteanu O, Furtunescu F, Lisievici AC, Grigoriu C, Gherghiceanu F, Vladareanu EM, Berceanu C, Ducu I, Iordache AM. Emerging Therapeutic Concepts and Latest Diagnostic Advancements Regarding Neuroendocrine Tumors of the Gynecologic Tract. Medicina (Kaunas). 2021 Dec 7;57(12):1338. doi: 10.3390/medicina57121338.

  PMID: 34946283 BACKGROUND

• Xu F, Yu Q, Wan D, Zhang Y. Cervical adenocarcinoma admixing with large cell neuroendocrine carcinoma: A rare case report. Asian J Surg. 2022 Dec;45(12):2932-2933. doi: 10.1016/j.asjsur.2022.06.109. Epub 2022 Jun 29. No abstract available.

  PMID: 35778245 BACKGROUND

• Salvo G, Gonzalez Martin A, Gonzales NR, Frumovitz M. Updates and management algorithm for neuroendocrine tumors of the uterine cervix. Int J Gynecol Cancer. 2019 Jul;29(6):986-995. doi: 10.1136/ijgc-2019-000504.

  PMID: 31263021 BACKGROUND

• Lee E, Ji YI. Large Cell Neuroendocrine Carcinoma of the Cervix with Sequential Metastasis to Different Sites: A Case Report. Case Rep Oncol. 2018 Oct 23;11(3):665-670. doi: 10.1159/000493912. eCollection 2018 Sep-Dec.

  PMID: 30483095 BACKGROUND

• Caruso G, Sassu CM, Tomao F, Di Donato V, Perniola G, Fischetti M, Benedetti Panici P, Palaia I. The puzzle of gynecologic neuroendocrine carcinomas: State of the art and future directions. Crit Rev Oncol Hematol. 2021 Jun;162:103344. doi: 10.1016/j.critrevonc.2021.103344. Epub 2021 Apr 29.

  PMID: 33933568 BACKGROUND

MeSH Terms

Conditions

Uterine Cervical Neoplasms

Condition Hierarchy (Ancestors)

Uterine Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Uterine Cervical Diseases; Uterine Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases

Central Study Contacts

Lin Shitong Doctor

CONTACT

86 02783662379; 1131108208@qq.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: OTHER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Associate Chief Physician

Study Record Dates

• First Submitted: November 15, 2025
• First Posted: November 21, 2025
• Study Start: December 1, 2025
• Primary Completion (Estimated): November 1, 2028
• Study Completion (Estimated): November 1, 2028
• Last Updated: November 21, 2025

Record last verified: 2025-06